Karyopharm Therapeutics I... (KPTI)
7.24
-0.71 (-8.93%)
At close: Mar 03, 2025, 3:59 PM
7.61
5.11%
After-hours: Mar 03, 2025, 04:01 PM EST
Karyopharm Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | 145.24M | 146.03M | 157.07M | 209.82M | 108.08M | 40.89M | 30.34M | 1.6M | 154K | 250K | 229K | 387K | 634K | 152K |
| Cost of Revenue | 6.01M | 4.94M | 5.21M | 3.4M | 2.71M | 2.41M | 161.37M | 107.27M | 86.94M | 97.74M | 60.13M | 28.45M | 14.1M | n/a |
| Gross Profit | 139.23M | 141.09M | 151.86M | 206.42M | 105.38M | 38.49M | -131.04M | -105.67M | -86.78M | -97.49M | -59.9M | -28.07M | -13.46M | 152K |
| Operating Income | -119.44M | -129.54M | -142.2M | -98.27M | -171.85M | -189.28M | -179.88M | -130.54M | -110.73M | -119.08M | -75.85M | -33.95M | -15.89M | -10.31M |
| Interest Income | 7.4M | 10.94M | 2.36M | 582K | 2.82M | 5.42M | 4.03M | 1.7M | 1.28M | 897K | 97K | 3K | 2K | n/a |
| Pretax Income | -76.36M | -142.78M | -164.92M | -123.82M | -195.96M | -199.55M | -178.38M | -128.92M | -109.44M | -118.18M | -75.78M | -33.95M | -15.89M | -10.31M |
| Net Income | -76.42M | -143.1M | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M | -128.98M | -109.58M | -118.18M | -75.78M | -33.95M | -15.89M | -10.31M |
| Selling & General & Admin | 115.44M | 131.88M | 145.4M | 143.85M | 126.42M | 105.42M | 48.85M | 24.87M | 23.95M | 21.58M | 15.95M | 5.88M | 2.43M | 1.84M |
| Research & Development | 143.23M | 138.75M | 148.66M | 160.84M | 150.81M | 122.34M | 161.37M | 107.27M | 86.94M | 97.74M | 60.13M | 28.45M | 14.1M | 8.62M |
| Other Expenses | n/a | n/a | -83K | -85K | 206K | -50K | -33K | -81K | 10K | -2K | -27K | n/a | n/a | n/a |
| Operating Expenses | 258.67M | 270.63M | 294.06M | 304.69M | 277.23M | 227.76M | 210.22M | 132.14M | 110.89M | 119.33M | 76.08M | 34.34M | 16.52M | 10.46M |
| Interest Expense | 37.42M | 23.82M | 25M | 26.05M | 27.14M | 15.65M | 2.49M | n/a | n/a | n/a | 1K | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 264.68M | 275.57M | 299.28M | 308.09M | 279.94M | 230.17M | 210.22M | 132.14M | 110.89M | 119.33M | 76.08M | 34.34M | 16.52M | 10.46M |
| Income Tax | 57K | 323K | 369K | 268K | 309K | 40K | 26K | 63K | 139K | -895K | -69K | -3K | -2K | n/a |
| Shares Outstanding (Basic) | 121.86M | 114.22M | 81.87M | 75.22M | 72.04M | 61.96M | 56.78M | 45.9M | 37.52M | 35.62M | 31.14M | 6.07M | 2.39M | 1M |
| Shares Outstanding (Diluted) | 126.81M | 114.22M | 81.87M | 75.22M | 72.04M | 61.96M | 56.78M | 45.9M | 37.52M | 35.62M | 31.14M | 6.07M | 2.39M | 1M |
| EPS (Basic) | -0.63 | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| EPS (Diluted) | -0.6 | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| EBITDA | -38.6M | -118.42M | -139.31M | -96.98M | -167.85M | -182.93M | -175.15M | -128.21M | -108.72M | -118.44M | -75.45M | -33.8M | -15.77M | -10.23M |
| Depreciation & Amortization | 340K | 530K | 621K | 789K | 972K | 974K | 735K | 713K | 717K | 634K | 323K | 144K | 122K | 83K |